Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China
- 191 Downloads
We reviewed 173 patients with an initial diagnosis of peripheral T-cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement (BMI) to those without to have a better understanding of the clinical characteristics, treatments, survival and prognosis of PTCLs with BMI. We found that 40% (70/173) of the patients had BMI, and its frequency was 64% in angioimmunoblastic T-cell lymphoma (TCL), 46% in PTCL unspecified, 29% in anaplastic large T-cell lymphoma, 23% in extranodal NK/T-cell lymphoma and 13% in enteropathy-type TCL. In the BMI group, 36% of patients had lymphoma-associated hemophagocytic syndrome (LAHS), compared with 8% of the patients without BMI (8/103, P < 0.001). The estimated 1-year overall survival (OS) rates of patients with LAHS in the BMI and non-BMI groups were 5 and 49%, respectively. The increased levels of lactate dehydrogenase, fasting triglycerides and β2-microglobulin between the BMI and non-BMI groups were not significantly different, but ferritin increased significantly and liver dysfunction-related diseases were seen more in the BMI group. As much as 51% of patients of the BMI group had anemia, compared with 27% of the patients without BMI (P = 0.001). The estimated 2-year OS rates in the two groups were 10 and 34%. The estimated 2-year OS rate of the 67 patients with BMI, who did not lose to follow-up, was 22%, compared with 38% in the non-BMI group. The median survival times of the 2 groups were 120 and 356 days. The estimated 2-year OS rate of patients treated by CHOP regimen was 9%, compared with 51% of those with intensive chemotherapy, with a significant difference (log rank P = 0.0008). The median survival time of the 14 patients subjected to chemotherapy combined with l-asparaginase was 365 days and that of the 7 patients undergoing hemopoietic stem cell transplantation (HSCT) was 575 days. A total of 3 patients in a critical condition underwent plasmapheresis as initial therapy and achieved stable condition. We conclude that patients with PTCLs with BMI on initial diagnosis usually have hemaphagocytic syndrome and poor prognosis. BMI without lymphadenopathy is a patent clinical feature in most PTCLs. Patients with anemia on initial diagnosis in the BMI group usually have poor prognosis than those without. Intense chemotherapy, addition of l-asparaginase in chemotherapy and HSCT are comparatively efficient treatments of PTCLs. For patients in critical conditions, plasmapheresis before chemotherapy would lower the risk and improve the tolerance to chemotherapy.
KeywordsT-cell lymphoma Bone marrow involvement Lymphoma-associated hemophagocytic syndrome Overall survival Chemotherapy
This work was supported by the Medical Science Research Fund of Zhejiang Province (No 2007B079) and also by the help of the Case Management Center of the First Affiliated Hospital of Medical College, Zhejiang University. We thank our interns for collecting and conducting the follow-up.
- 1.The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.Google Scholar
- 7.López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol. 1998;9(8):849–55. doi: 10.1023/A:1008418727472.CrossRefPubMedGoogle Scholar
- 13.Tong H, Ren Y, Liu H, Xiao F, Mai W, Meng H, et al. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma. 2008;49(1):81–7. doi: 10.1080/10428190701713630.CrossRefPubMedGoogle Scholar
- 15.Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110(4):1278–82. doi: 10.1182/blood-2007-01-070300.CrossRefPubMedGoogle Scholar
- 16.Peng YL, Huang HQ, Zhou ZM, Lin XB, Pang ZH, Guan ZZ. Clinical outcome of 117 patients with peripheral T-cell lymphomas, unspecified. China Oncol. 2006;16:132–5.Google Scholar
- 18.Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer. 2004;101(7):1601–8. doi: 10.1002/cncr.20531.CrossRefPubMedGoogle Scholar
- 20.Arrowsmith ER, Macon WR, Kinney MC, Stein RS, Goodman SA, Morgan DS, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American Lymphoma Classification. Leuk Lymphoma. 2003;44(2):241–9. doi: 10.1080/1042819021000030054.CrossRefPubMedGoogle Scholar
- 21.Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Non-Hodgkin’s Lymphoma Classification Project: peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma) results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13(1):140–9. doi: 10.1093/annonc/mdf033.CrossRefPubMedGoogle Scholar